British Biotech plc  by unknown
that, in addition to Hedgehog motifs,
other motifs associated with a Hog
domain will be found in higher
animals.
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What is it famous for?  Being a high-
profile biotechnology company
despite being based in the UK. It
was the first biotechnology company
to be listed on the London stock
exchange; it is now one of about 20.
How did it start? It was founded in
July 1986 by two scientists from G.D.
Searle & Co., a British
pharmaceutical company, when
Monsanto bought Searle and
promptly closed it. Keith McCullagh,
one of the founders, is now the CEO;
the other, Brian Richards, was
Chairman until the end of 1994.
What does it do?  British Biotech’s
focus from the start has been cancer
therapeutics, in particular the matrix
metalloproteinases (MMPs) that
appear to be important in tissue
invasion by malignant cells. Its most
promising product at present is an
orally active MMP inhibitor, originally
given the evocative name BB-2516
but now known as marimastat, which
is currently in phase III clinical trials
for pancreatic cancer.
Are all the company’s eggs in the
MMP basket?  No. Other drugs in
clinical trials include lexipafant, a
platelet-activating factor inhibitor
now in phase III trials for pancreatitis
and phase II for other indications, and
BB10010, an engineered version of
macrophage inflammatory protein-1a
that is intended to protect stem cells
during chemotherapy (currently in
phase II trials). Phase II trials of p24-
VLP, a “virus-like-particle” and
candidate HIV therapeutic vaccine,
proved “less than encouraging” and
were dropped.
How is the company funded?  Mostly
by stock sales; there is no income
from drugs as yet. It recently
launched a rights issue to raise £143
million (about $212 million), thought
to be the largest amount ever raised
by a biotech company. Less than half
of the shares were taken up by
existing shareholders, however; this
was disappointing, but not fatal, as
underwriters made up the difference.
Why did it need to raise more money?
Although British Biotech’s cash
reserves stood at around £66 million
before the rights issue, the company
plans extensive (and expensive)
clinical trials for both of its lead
products in the near future. The
company claims that this should be
the last time it needs to appeal to the
stock market for cash before the
money from hoped-for drug sales
starts coming in. The company also
wants to consolidate its UK operations
at a new site in Cowley, Oxford.
Does the company have any presence
in the US?  Yes. British Biotech Inc.
was founded in 1993 in Annapolis.
It’s responsible for clinical trials in
the US, and for dealing with the US
Food and Drug Administration.
Why are there so few biotechnology
companies in the UK?  British
Biotech’s success in raising money
suggests that the problem is not one of
funding. The lack of entrepreneurial
spirit in the ‘old country’ is a popular
explanation, as always; the fact that
venture capitalists are less aggressive
outside the US may also be a factor.
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